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Abstract: Altered cell surface glycosylation in congenital and acquired diseases has been shown
to affect cell differentiation and cellular responses to external signals. Hence, it may have an
important role in immune regulation; however, T cell surface glycosylation has not been studied
in systemic lupus erythematosus (SLE), a prototype of autoimmune diseases. Analysis of the
glycosylation of T cells from patients suffering from SLE was performed by lectin-binding assay, flow
cytometry, and quantitative real-time PCR. The results showed that resting SLE T cells presented an
activated-like phenotype in terms of their glycosylation pattern. Additionally, activated SLE T cells
bound significantly less galectin-1 (Gal-1), an important immunoregulatory lectin, while other lectins
bound similarly to the controls. Differential lectin binding, specifically Gal-1, to SLE T cells was
explained by the increased gene expression ratio of sialyltransferases and neuraminidase 1 (NEU1),
particularly by elevated ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 (ST6GAL1)/NEU1 and
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (ST3GAL6)/NEU1 ratios. These findings indicated
an increased terminal sialylation. Indeed, neuraminidase treatment of cells resulted in the increase
of Gal-1 binding. Altered T cell surface glycosylation may predispose the cells to resistance to the
immunoregulatory effects of Gal-1, and may thus contribute to the pathomechanism of SLE.
Keywords: systemic lupus erythematosus; T cells; glycosylation; sialylation; lectin binding;
glycosylation enzymes; galectin 1
1. Introduction
Numerous congenital and acquired diseases show altered cell surface glycosylation, including
several types of cancer and autoimmune syndromes [1,2]. Altered oligosaccharide structures have
been identified in tumors and have proven to be diagnostic markers of malignant phenotypes [1,3,4].
Protein glycosylation has become an integral part of research in autoimmunity, as defective glycan
structures have been described on serum immunoglobulins [5] and the different glycans at certain
residues on IgG subclasses affected the effector function of autoantibodies [6,7]. Surface glycosylation
of immune cells has also been studied, and glycoconjugates have been proven to play a role in many
fields of cellular physiology, such as migration and signal transduction [8]. T cell functions can also
be modulated by interaction between cell surface glycoproteins and endogenous lectins, including
galectins [9].
Glycoconjugates are created in the endoplasmic reticulum, the Golgi apparatus, and on the
cell surface by enzymes, including mannosidases, glycosyltransferases, sialyltransferases, and
neuraminidases (NEU) [10]. The concerted action of these enzymes produces the specific sugar
Int. J. Mol. Sci. 2019, 20, 4455; doi:10.3390/ijms20184455 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 4455 2 of 14
‘code’ presented on the cell surface, which then regulates further signaling and adhesion properties
of a particular cell type. The expression of enzymes participating in glycosylation can determine the
sensitivity of the cells to numerous extracellular signals.
Galectin 1 (Gal-1) is a member of the β-galactoside binding mammalian lectin family with specific
affinity to terminal N-acetyllactosamine motifs on multi-antennary cell surface glycans [11]. One of
the major effects of Gal-1 in immunoregulation is the induction of apoptosis of the activated T cell
subpopulations Th1 and Th17, whereas Th2 and Treg cell functions are promoted by Gal-1 [12,13].
This selectivity is caused by the differences in surface glycosylation of various T cell subtypes [9].
Gal-1-triggered cell death has been extensively studied in vitro, and its mechanism has been
described [14–18]. Lactosamine sequences, required for Gal-1 binding, are synthesized by specific
glycosyltransferases, such as beta-N-acetylglucosaminyltransferases and beta-galactosyltransferases.
The expression of such enzymes controls T cell susceptibility to Gal-1-driven apoptosis [19].
We have recently demonstrated that activated T cells from patients with active systemic lupus
erythematosus (SLE) are resistant to the apoptotic effect of Gal-1 [20], and we suggested that this
finding is relevant to the immunoregulatory dysfunction observed in SLE. As a potential cause of this
resistance may be an impaired binding of Gal-1 to the T cell surface, we set out to examine cell surface
glycosylation and the expression of glycosylation enzymes in SLE T cells in comparison with healthy
control T cells. The glycosylation pattern of resting SLE T cells resembled the activated phenotype of
T cells. Activated SLE T cells bound significantly less galectin 1 (Gal-1) than the controls, while other
lectins bound similarly. To understand the distinct lectin binding, specifically Gal-1, to SLE T cells, we
found that the terminal sialylation increased in the autoimmune cells, and accordingly, neuraminidase
treatment resulted in a remarkable increase in Gal-1 binding.
2. Results
The N-glycome diversity of T cell surface glycans was analyzed by the binding of lectins derived
from plants (concanavalin-A (ConA), Lens culinaris agglutinin (LCA), wheat germ agglutinin (WGA),
Phaseolus vulgaris leukoagglutinin (PHA-L), and Sambucus nigra agglutinin (SNA)) or of a human
lectin, Gal-1, with known sugar binding specificity (Figure S1 and Table 1). Lectin binding to resting
and phytohaemagglutinin (PHA)-activated T cells obtained from SLE patients and healthy controls
was measured. Analysis of resting T cells from SLE patients and control individuals revealed that
resting SLE T cells bound significantly more ConA, LCA, and WGA than healthy T cells (Figure 1A).
ConA couples with mannoses present in early high-mannose glycans and mannoses in complex
sugars [21,22], while LCA has high affinity to fucosylated core mannoses present in bi-antennary
complex N-glycans and does not bind to tri- and tetra-antennary N-glycans [23]. WGA binds to
N-acetyl glucosamines present in hybrid-type sugar chains (early and complex sugars) or to sialic acid,
which can be terminally attached to complex multi-antennary glycans, and its affinity to the sialylated
version of tri- or tetra-antennary glycan-containing glycoproteins was shown to be higher than to the
desialylated form [24,25].
Table 1. Names, abbreviations, and binding specificities of lectins.
Lectins Abbreviation Specificity Reference
Concanavalin A ConA mannose, glucose (low affinity) [21,22]
Lens culinaris agglutinin LCA core-fucosylated bi-antennary N-glycan [22,23]
Wheat germ agglutinin WGA GlcNAc, sialic acid [24,25]
Phaseolus vulgaris leucoagglutinin PHA-L β-1,6-branched tri- and tetra-antennaryN-glycans [26]
Sambucus nigra agglutinin SNA α-2,6-linked sialic acid [27]
Galectin-1 Gal-1 LAcNAc [28]
Abbreviation: GlcNAc: N-acetylgucosamine; LacNAc: N-acetyllactoseamine.
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Figure 1. Lectin binding properties of resting and activated T cells from healthy donors and from 
systemic lupus erythematosus (SLE) patients. Peripheral blood T cells were obtained from healthy 
controls and SLE patients. The cells were left unstimulated (resting state, A) or were activated with 1 
µg/mL phytohaemagglutinin L (PHA L) for 72 h (activated state, B). Cells were stained with viability 
dye, fixed then labeled with anti-CD3-PE-Cy5 antibody, followed by fluorescein isothiocyanate 
(FITC)-conjugated lectin. The samples were evaluated with flow cytometry. Binding of FITC-
conjugated lectins is shown as mean (±SEM) of the median fluorescence intensity (MFI) values of flow 
cytometry histograms of resting (A) or activated (B) CD3-positive live T cells. Lectin names are listed 
in Table 1. MFI: mean fluorescence intensity, ConA: concanavalin-A, LCA: Lens culinaris agglutinin, 
WGA: wheat germ agglutinin, PHA-L: Phaseolus vulgaris leukoagglutinin, SNA: Sambucus nigra 
agglutinin, Gal-1: galectin 1. Statistical analysis was performed using an unpaired Student t-test. ** p 
< 0.01; *** p < 0.001; n. s.: not significant. SLE: n = 18, and healthy controls: n = 19. 
Comparing healthy and autoimmune-activated T cells, we found that activated SLE T cells 
bound lectins in levels similar to control cells with the exception of Gal-1. SLE cells bound 
significantly less Gal-1 than control cells, indicating that terminal N-acetyllactosamine side chains, 
the Gal-1 ligands, were less accessible on these cells (Figure 1B). The changes in the pattern of lectin 
bindings did not occur preferentially on either CD4+ or CD4- (CD8+) cells, as these were similar in 
the control as well as in SLE activated T cells (Figure S2). 
Glycosylation of proteins is regulated by multiple factors in the Golgi apparatus, such as sub-
Golgi localization of glycosylation enzymes, transporters, pH, endoplasmic reticulum stress, or 
substrate availability (reviewed in [29]). However, a major element is the expression and function of 
glycosylation enzymes [30,31]. Therefore, expression levels of the genes involved in N-linked 
glycosylation (Figure S1 and Table 2) were examined by qPCR analysis of activated T cells. Gene 
expression of alpha mannosidases (MAN1A1, MAN1A2, MAN2A1 and MAN2A2) in activated SLE T 
cells did not differ from the controls (Figure 2A). Analysis of beta-N-acetylglucosaminyltransferases 
(MGAT1–5) presented a slight but significant difference in the cases of MGAT4A and MGAT4B 
(Figure 2B). 
Figure 1. Lectin binding properties of resting and activated T cells from healthy donors and from
systemic lupus erythematosus (SLE) patients. Peripheral blood T cells were obtained from healthy
controls and SLE patients. The cells were left unstimulated (resting state, A) or were activated
with 1 µg/mL phytohaemagglutinin L (PHA L) for 72 h (activated state, B). Cells were stained with
viability dye, fixed then labeled with anti-CD3-PE-Cy5 antibody, followed by fluorescein isothiocyanate
(FITC)-conjugated lectin. The samples were evaluated with flow cytometry. Binding of FITC-conjugated
lectins is shown as mean (±SEM) of the median fluorescence intensity (MFI) values of flow cytometry
histograms of resting (A) or activated (B) CD3-positive live T cells. Lectin names are listed in Table 1.
MFI: mean fluorescence intensity, ConA: concanavalin-A, LCA: Lens culinaris agglutinin, WGA: wheat
germ agglutinin, PHA-L: Phaseolus vulgaris leukoagglutinin, SNA: Sambucus nigra agglutinin, Gal-1:
galectin 1. Statistical analysis was performed using an unpaired Student t-test. ** p < 0.01; *** p < 0.001;
n. s.: not significant. SLE: n = 18, and healthy controls: n = 19.
Comparing healthy and autoimmune-activated T cells, we found that activated SLE T cells bound
lectins in levels similar to control cells with the exception of Gal-1. SLE cells bound significantly less
Gal-1 than control cells, indicating that terminal N-acetyllactosamine side chains, the Gal-1 ligands,
were less accessible on these cells (Figure 1B). The changes in the pattern of lectin bindings did not
occur preferentially on either CD4+ or CD4- (CD8+) cells, as these were similar in the control as well
as in SLE activated T cells (Figure S2).
Glycosylation of proteins is regulated by multiple factors in the Golgi apparatus, such as
sub-Golgi localization of glycosylation enzymes, transporters, pH, endoplasmic reticulum stress, or
substrate availability (reviewed in [29]). However, a major element is the expression and function
of glycosylation enzymes [30,31]. Therefore, expression levels of the genes involved in N-linked
glycosylation (Figure S1 and Table 2) were examined by qPCR analysis of activated T cells. Gene
expression of alpha mannosidases (MAN1A1, MAN1A2, MAN2A1 and MAN2A2) in activated SLE
T cells did not differ from the controls (Figure 2A). Analysis of beta-N-acetylglucosaminyltransferases
(MGAT1–5) presented a slight but significant difference in the cases of MGAT4A and MGAT4B
(Figure 2B).
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Table 2. Symbols and full names of glycosylation enzyme genes.
Enzyme Genes Gene Symbol Full Gene Name
Mannosidases MAN1A1 Mannosidase alpha class 1A member 1
MAN1A2 Mannosidase alpha class 1A member 2
MAN2A1 Mannosidase alpha class 2A member 1
MAN2A2 Mannosidase alpha class 2A member 2
N-Acetylglucosaminyltransferase MGAT1 Mannosyl (alpha-1,3-)-glycoproteinbeta-1,2-N-acetylglucosaminyl-transferase
MGAT4A Mannosyl (alpha-1,3-)-glycoproteinbeta-1,4-N-acetylglucosaminyl-transferase isozyme A
MGAT4B Mannosyl (alpha-1,3-)-glycoproteinbeta-1,4-N-acetylglucosaminyl-transferase isozyme B
MGAT5 Mannosyl (alpha-1,6-)-glycoproteinbeta-1,6-N-Acetyl-glucosaminyltransferase
Sialyltransferases ST3GAL3 ST3 beta-galactosidealpha-2,3-sialyltransferase 3
ST3GAL4 ST3 beta-galactosidealpha-2,3-sialyltransferase 4
ST3GAL6 ST3 beta-galactosidealpha-2,3-sialyltransferase 6
ST6GAL1 ST6 beta-galactosamidealpha-2,6-sialyltranferase 1
Neuraminidases NEU1 Neuraminidase 1Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 15 
 
 
Figure 2. Gene expression of mannosidases (MANs) (A) and N-acetyl glucosaminyltransferases 
(MGATs) (B) in activated T cells. Total RNA was extracted from activated T cells and mRNA 
expression levels were analyzed by qPCR. Results of the relative expression were normalized to the 
expression levels of the RPL27 housekeeping gene (log2 transformation, ΔCt). Gene names and primer 
sequences are listed in Table 2 and 4, respectively. Upper and lower quartiles and whiskers of boxes 
extend to the minimum and maximum values, and the band inside the box is the median. Statistical 
analysis was performed using an unpaired Student’s t-test, where * p < 0.05; SLE: n = 18, and healthy 
controls: n = 19. 
Poly-N-acetyllactosamine chains on N glycans can be capped with the attachment of α-2,6 sialic 
acid by ST6 beta-galactosamidealpha-2,6-sialyltranferase 1 (ST6GAL1) and α-2,3 sialic acid by 
ST3GAL3, ST3GAL4, and ST3GAL6 [32],and cleaved by neuraminidases. In the control and patient 
groups, ST6GAL1, ST3GAL3, ST3GAL4, and neuraminidase 1 (NEU1) gene expression levels were 
similar, whereas the mRNA level of ST3GAL6 was significantly elevated in SLE T cells (Figure 3A). 
During T cell activation, the gene expression of NEU1 is strongly upregulated, while NEU3 
expression remains constant [33]; hence, only NEU1 was analyzed. 
Figure 2. Gene expression of mannosidases (MANs) (A) and N-acetyl glucosaminyltransferases
(MGATs) (B) in activated T cells. Total RNA was extracted from activated T cells and mRNA expression
levels were analyzed by qPCR. Results of the relative expression were normalized to the expression
levels of the RPL27 housekeeping gene (log2 transformation, ∆Ct). Gene names and primer sequences
are listed in Table 2 and Table 4, respectively. Upper and lower quartiles and whiskers of boxes extend
to the minimum and maximum values, and the band inside the box is the median. Statistical analysis
was performed using an unpaired Student’s t-test, where * p < 0.05; SLE: n = 18, and healthy controls:
n = 19.
Poly-N-acetyllactosamine chains on N glycans can be capped with the attachment of α-2,6
sialic acid by ST6 beta-galactosamidealpha-2,6-sialyltranferase 1 (ST6GAL1) and α-2,3 sialic acid by
ST3GAL3, ST3GAL4, and ST3GAL6 [32],and cleaved by neuraminidases. In the control and patient
groups, ST6GAL1, ST3GAL3, ST3GAL4, and neuraminidase 1 (NEU1) gene expression levels were
similar, whereas the mRNA level of ST3GAL6 was significantly elevated in SLE T cells (Figure 3A).
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During T cell activation, the gene expression of NEU1 is strongly upregulated, while NEU3 expression
remains constant [33]; hence, only NEU1 was analyzed.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 15 
 
 
Figure 3. Gene expression of sialyltransferases (ST) and neuraminidase-1 (NEU1) in activated T cells. 
Total RNA was extracted from activated T cells and mRNA expression levels were analyzed by qPCR. 
(A) Results of the relative expression were normalized to the expression levels of RPL27 housekeeping 
gene (log2 transformation, ΔCt). Gene names and primer sequences are listed in Table 2 and 4, 
respectively. (B) ST/NEU1 mRNA expression ratios. The sialyltransferase-neuraminidase mRNA 
expression ratios of individual persons were calculated as follows: ΔCt ST/ΔCtNEU1. Upper and 
lower quartiles and whiskers of boxes extend to the minimum and maximum values, and the band 
inside the box is the median. Statistical analysis was performed using an unpaired Student t-test, 
where ** p< 0.01; *** p< 0.001. SLE: n = 18, and healthy controls: n = 19. 
Concerted action of sialyltransferases and neuraminidases determine the sialylation pattern. The 
large variations between the Gal-1 binding of the control and SLE T cells (Figure 1B) indicated an 
alteration in the sialylation of SLE surface glycans. As this is determined by the net effect of enzymes 
that sialylate (sialyltransferase) and desialylate (neuraminidase) the glycans, gene expression ratios 
of the opposing acting enzymes were calculated. A significantly higher ST3GAL6/NEU1 and 
ST6GAL1/NEU1 mRNA ratio was observed in SLE compared to control T cells (Figure 3B), indicating 
higher sialylation of SLE T cells. Other sialyltransferase/neuraminidase mRNA ratios, such as 
ST3GAL3/NEU1 andST3GAL4/NEU1, remained similar in the control and SLE groups (Figure 3B). 
These results indicated that reduced Gal-1 binding to SLE T cells may be a result of a more densely 
sialylated glycan profile. Indeed, cleaving sialic acid from the surface of SLE activated T cells by α2-
3,6,8 Neu (specific to α2-3,6,8 linked sialic acid) resulting in the elevation of Gal-1 binding (Figure 4). 
The increase of Gal-1 binding to SLE cells was similar to that of control T cells (data not shown). 
Figure 3. Gene expression of sialyltransferases (ST) and neuraminidase-1 (NEU1) in activated T cells.
Total RNA was extracted from activated T cells and mRNA expression levels were analyzed by qPCR.
(A) Results of the relative expression were normalized to the expression levels of RPL27 housekeeping
gene (log2 transformation, ∆Ct). Gene names and primer sequences are listed in Table 2 and Table
4, respectively. (B) ST/NEU1 mRNA expression ratios. The sialyltransferase-neuraminidase mRNA
expression ratios of individual persons were calculated as follows: ∆Ct ST/∆CtNEU1. Upper and lower
quartiles and whiskers of boxes extend to the minimum and maximum values, and the band inside
the box is the median. Statistical analysis was performed using an unpaired Student t-test, where
** p< 0.01; *** p< 0.001. SLE: n = 18, and healthy controls: n = 19.
Concerted action of sialyltransferases and neuraminidases determine the sialylation pattern.
The large variations between the Gal-1 binding of the control and SLE T cells (Figure 1B) indicated
an alteration in the sialylation of SLE surface glycans. As this is determined by the net effect of
enzymes that sialylate (sialyltransferase) and desialylate (neuraminidase) the glycans, gene expression
ratios of the opposing acting enzymes were calculated. A significantly higher ST3GAL6/NEU1
and ST6GAL1/NEU1 mRNA ratio was observed in SLE compared to control T cells (Figure 3B),
indicating higher sialylation of SLE T cells. Other sialyltransferase/neuraminidase mRNA ratios, such
as ST3GAL3/NEU1 andST3GAL4/NEU1, remained similar in the control and SLE groups (Figure 3B).
These results indicated that reduced Gal-1 binding to SLE T cells may be a result of a more densely
sialylated glycan profile. Indeed, cleaving sialic acid from the surface of SLE activated T cells by
α2-3,6,8 Neu (specific to α2-3,6,8 linked sialic acid) resulting in the elevation of Gal-1 binding (Figure 4).
The increase of Gal-1 binding to SLE cells was similar to that of control T cells (data not shown).
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Figure 4. Effect of neuraminidase treatment on Gal-1 binding of SLE T cells. Activated SLE 
T cells were treated with α2-3,6,8 neuraminidase (Gal-1 + α2-3,6,8 Neu; dotted line) or left 
untreated (Gal-1; empty, continuous line), and then Gal-1 binding was investigated by 
cytofluorimetry, as described in the materials and methods section. The grey shadowed 
histogram shows the negative control: no Gal-1, +streptavidin—FITC. The upper image 
shows a representative profile of Gal-1 binding, the lower graph shows means (±SEM) of 
the mean fluorescence intensity (MFI) values of activated SLE T cells. Statistical analysis 
was performed using a two-tailed paired t-test. * p < 0.05, n = 3. 
3. Discussion 
Selected steps of mammalian N linked glycosylation and lectin binding to specific sugar side 
chains are summarized in Figure S1. It must be noted that binding of the used lectins was more 
degenerated than what is shown in the simplified Figure S1; however, it may help in a better 
apprehension of this work. 
Remarkable differences were detected in ConA, LCA, and WGA binding between resting SLE 
and control T cells, since SLE T cells bound significantly higher amounts of these lectins. As LCA and 
WGA recognize matured sugar side chains and ConA couples both unmatured (early) and matured 
(complex) glycans, these results indicated that resting SLE T cells present a glycan structure similar 
to their activated phenotype. Detection of other activation markers, such as heightened CD40L 
expression [34], CD44 expression [35–37], exhibition of constant membrane raft polarization and 
increased GM1 content [38], measured by others, also suggest similarity to an activated state. On the 
other hand, this activated phenotype did not manifest in terms of CD25 expression on resting SLE T 
cells, as CD25 levels were similar on resting and activated T cells, suggesting that the activated 
phenotype is limited to several, but not all activation markers (Figure S3). 
Stimulation of control T cells with PHA-L resulted in an elevation of binding of all used lectins, 
except the terminal α-2,6 sialic acid binding SNA (data not shown), indicating a generally increased 
complexity of glycosylation pattern upon activation. These results were in accordance with previous 
findings, arguing that N-glycan abundance, branching, glycan chain elongation, and hereby 
complexity enhanced [39,40], and terminal α-2,6 sialic acid residues declined [41–43] on freshly 
activated T cells. However, the increase in glycan complexity after activation was hardly seen in SLE 
T cells, as an increase in lectin binding upon activation was rather low or was absent in SLE, a 
phenomenon that is also explained by the activated phenotype of SLE T cells, even without treatment 
with activating agents. Furthermore, the decreased Gal-1 binding of SLE T cells was observed, not 
only in resting state, but also persisting after activation. No difference was found between CD4+ and 
Figure 4. Effect of neuraminidase treatment on Gal-1 binding of SLE T cells. Activated SLE T cells
were treated with α2-3,6,8 neuraminidase (Gal-1 + α2-3,6,8 Neu; dotted line) or left untreated (Gal-1;
empty, continuous line), and then Gal-1 binding was investigated by cytofluorime ry, as described in
the materials nd methods sectio . The grey shadowed histogram shows the negative control: no
Gal-1, +strep avidin—FITC. The upper image shows a representative profile of Gal-1 bin ing, the
lower graph shows means (±SEM) f the mean fluorescenc intensity (MFI) values of activated SLE
T cells. Statistical analysis was performed using a two-tailed paired t-test. * p < 0.05, n = 3.
3. Discussion
Selected steps of mammalian N linked glycosylation and lectin binding to specific sugar side chains
are summarized in Figure S1. It must be noted that binding of the used lectins was more degenerated
than what is shown in the simplified Figure S1; however, it may help in a better apprehension of
this work.
Remarkable differences were detected in ConA, LCA, and WGA binding between resting SLE
and control T cells, since SLE T cells bound significantly higher amounts of these lectins. As LCA and
WGA recognize matured sugar side chains and ConA couples both unmatured (early) and matured
(complex) glycans, these results indicated that resting SLE T cells present a glycan structure similar
to their activated phenotype. Detection of other activation markers, such as heightened CD40L
expression [34], CD44 expression [35–37], exhibition of constant membrane raft polarization and
increased GM1 content [38], measured by others, also suggest similarity to an activated state. On the
other hand, this activated phenotype did not manifest in terms of CD25 expression on resting SLE
T cells, as CD25 levels were similar on resting and activated T cells, suggesting that the activated
phenotype is limited to several, but not all activation markers (Figure S3).
Stimulation of control T cells with PHA-L resulted in an elevation of binding of all used lectins,
except the terminal α-2,6 sialic acid binding SNA (data not shown), indicating a generally increased
complexity of glycosylation pattern upon activation. These results were in accordance with previous
findings, arguing that N-glycan abundance, branching, glycan chain elongation, and hereby complexity
enhanced [39,40], and terminal α-2,6 sialic acid residues declined [41–43] on freshly activated T cells.
However, the increase in glycan complexity after activation was hardly seen in SLE T cells, as an
increase in lectin binding upon activation was rather low or was absent in SLE, a phenomenon that
is also explained by the activated phenotype of SLE T cells, even without treatment with activating
agents. Furthermore, the decreased Gal-1 binding of SLE T cells was observed, not only in resting
state, but also persisting after activation. No difference was found between CD4+ and CD4- (CD8)
cells in terms of binding of any of the lectins (Figure S2). Some previous findings indicate that the
proportion of effector memory (C-C Motif Chemokine Receptor 7{CCR7}-CD27+) and terminally
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differentiated effector memory (CCR7-CD27-) cells increase in SLE, and may correlate with disease
activity or damage [44,45]. It would be interesting to compare the cell surface glycosylation patterns of
naive and various subtypes of memory T cells; however, it was outside the scope of our present study.
It is also to be noted that SLE memory effector T cells are crippled in response to antigen stimulation, as
they respond to stimulation with apoptosis instead of proliferation [45], which might be a consequence
of the altered glycosylation.
Variation in the binding of lectins tested was only confined to Gal-1, whose binding is determined
by the presence of asialylated terminal N-acetyl lactose residues [46]. To clarify the background
of this specific variability of Gal-1 binding, the expression of enzymes involved in creating the
glycosylation pattern was determined. Analysis of the mRNA expression of glycosylation enzymes was
chosen, since previous data indicated that glycosylation was primarily regulated at the transcriptional
level of the appropriate enzymes [31]. Expressions of glycosyltransferases, alpha mannosidases,
beta-N-acetylglucosaminetransferases, sialytransferases, and a neuraminidase, NEU1, were similar in
control and SLE T cells. These findings are in accordance with the results of lectin assays, as all lectins
tested bound similarly to the activated control and autoimmune T cells, with the exception ofGal-1.
The difference in Gal-1 binding between control and patient activated T cells might therefore result
from the distinct sialylation of the Gal-1 binding glycoconjugates. This presumption seemed to be
supported by the finding that ratios of the expression of sialyltransferases (ST3GAL6 and ST6GAL1)
and neuraminidase shifted towards the sialytransferases, indicating a more intensified sialylation of
SLE T cell glycans, including Gal-1 binding structures. Sialylation plays an important role in masking
terminal carbohydrate chains, hence regulating lectin binding and signal transduction processes.
Sialyltransferases attach, while neuraminidases remove sialic acid residues of terminal carbohydrate
groups. Consequently, the accessibility of lectin binding sites is specifically regulated by the concerted
action of sialyltransferases and neuraminidases. This point of view was supported with the finding,
that ablation of sialic acid from surface glycoconjugates of living activated SLE T cells by neuraminidase
treatment resulted in an increase in Gal-1 binding.
An important issue is how glycosylation affects autoimmune T cell activation, cell–cell interactions
and autoantibody production. The available literature data are limited, and further detailed
investigation is required. However, several studies suggest that pathological glycosylation results
in disturbed T cell receptor (TCR)-major histocompatibility complex (MHC) interactions [38], cell
adhesion [40], necrotic cell death- and glycan-specific autoantibody production [47], and deviant
antigen presentation [48,49]. How closely the pathomechanism of SLE is associated with the surface
glycosylation pattern and its abnormalities remains to be elucidated. Nevertheless, the present
findings seem to corroborate our hypothesis regarding the resistance of activated SLE T cells to the
apoptotic effects of Gal-1. As we described earlier [20], activated SLE T cells showed a reduced
response to Gal-1 due to their defective expression of intracellular Gal-1. The present work suggests
that altered glycosylation and, hence, the decreased binding of extracellular Gal-1 to SLE T cells can
be another cause of the resistance to Gal-1-mediated immunomodulation, serving a putative novel
pathogenic mechanism in SLE. It has to also be clarified whether removal of sialic acid from cell
surface glycoconjugates results in the restoration of Gal-1-induced apoptotic sensitivity. Nevertheless,
it has become clear from this work that analyzing the glycosylation process, especially the expression
ratio of sialyltransferases and the neuraminidases and the binding of Gal-1 to the cell surface, may
emerge as a novel approach to connecting disease phenotypes with functional pathways within T cells
(differential-diagnosis of diseases or patient subset analysis within particular multisystem autoimmune
diseases).
Since SLE is an autoimmune disease with multiple alterations on genetic, protein, signaling, and
glycosylation levels, it is difficult to determine the primary cause of the disorder. It is likely that all the
more-or-less relational changes result in the final manifestation of SLE. As glycosylation affects cell
migration, adhesion, and signal transduction, its changes must be an important factor contributing to
the pathomechanism of the disease. This view is supported by the finding that the binding of Gal-1
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to SLE T cells, an anti-inflammatory human lectin, decreases because of the different sialylation of
SLE T cells from that of healthy T cells, and thus it must be another reason that SLE T cells are more
resistant to Gal-1-induced apoptosis [20].
The glycosylation phenotype resembles an activated state of SLE T cells. Though the fundamental
causes behind the development of SLE are unclear, it is known that alpha-mannosidase II knock out mice
develop an SLE-like disease [50]. This enzyme removes early mannose from maturing glycoconjugates,
therefore, it is crucial to the final formation of healthy complex N-glycan structures observed in
mammals. Its deficiency leads to immature, mannose-rich glycan chains being upregulated because of
a disruption in their stepwise disassembly before the complex chain can be built in their place [51].
This effect is similar to our findings indicating a higher-than-normal distribution of mannose-rich
glycans on SLE T cells before activation. It is known that mannose-rich chains are much more common
on many strains of fungi and are easily recognized as non-self structures leading to auto-immune
reactions [50].
Altered glycosylation in SLE is not confined to T cells, as the glycan profile of IgG is a primary
predictor of the inflammatory capability of the molecule. Asialylated, agalactosylated glycan chains
are stronger activators of complement than sialylated chains, and as such, pro-inflammatory responses
are upregulated by the IgG molecule if it contains less terminal syalic acid units [5].
Altogether, the above data indicate that alteration in glycosylation in SLE is likely to be a primary
phenomenon, and it contributes to the pathomechanism of the disease.
To our knowledge, the current work provides the first evidence for altered T cell surface
glycosylation in SLE. Our major findings are that resting SLE T cells show an activated phenotype from
the glycosylation point of view and lectin binding of activated SLE T cells is similar to the controls, with
exception of the significantly lower Gal-1 binding. Furthermore, this is a consequence of a shift toward
terminal sialylation of glycan structures due to an increased ST6GAL1/NEU1 and/or ST3GAL6/NEU1
ratio. Indeed, desialylation of the surface glycans on SLE T cells results in a remarkable increase in
Gal-1 binding.
4. Materials and Methods
4.1. Ethical Statement
The study was designed in accordance with the guidelines of the Declaration of Helsinki and was
approved by the Human Investigation Review Board, University of Szeged reference, No. 2833/2011
on 21 February 2011.
4.2. Patients
Patients with SLE (n = 18) and healthy controls (n = 19) were examined, except in one experiment
where n = 3 (Figure 3). All patients met the 2012 SLICC classification criteria for SLE [52,53] and
had active disease, as reflected by relevant disease activity indices. Eligible patients had an SLE
Disease Activity-Index-2000 (SLEDAI-2K) ≥ 6 [54], did not have a co-existent inflammatory condition
(overlapping autoimmune disease or infection), and did not have diabetes mellitus. Treatment
with potent immunosuppressive drugs (mycophenolate mofetil, cyclophosphamide, rituximab) or
corticosteroid at a dose >5 mg prednisolone equivalent was also an exclusion criterion. Controls were
healthy individuals without any inflammatory disease or diabetes mellitus.
Demographics and the relevant disease activity data are presented in Table 3.
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Table 3. Demographics and disease activity parameters. Numbers before and in brackets indicate
mean and range, respectively. SLEDAI-2K: SLE Disease Activity-Index-2000, anti-dsDNA: antibody to
double-stranded DNA.
Subject Characteristics Age Female/Male Disease Activity Parameter
SLE 42 (23–54) 17/1
SLEDAI-2K 14 (6–30)
anti-dsDNA (IU/mL) 88 (2–220)
Control 54 (31–75) 17/2
4.3. Cells
Peripheral blood mononuclear cells (PBMC) were isolated from SLE patients and healthy donors
using Ficoll (GE Healthcare, Amersham, UK) gradient centrifugation. A part of the PBMCs was
stimulated with 1 µg/mL phytohaemagglutinin-L (PHA-L, Sigma-Aldrich, St. Louis, MO, USA) and
the cells were cultured for 72 h in a humidified incubator with 5% CO2 at 37 ◦C in Roswell Park
Memorial Institute (RPMI)-1640 medium (Gibco, Life Technologies, Paisley, UK) supplemented with
10% fetal bovine serum (FBS) (Gibco, Life Technologies, Paisley, UK), 2 mM L-glutamine (Gibco,
Life Technologies, Paisley, UK) and penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, USA),
henceforward referred to as activated T cells. Activated T cell cultures were > 90% pure, as controlled
with flow cytometry using anti-human CD3 antibody (BioLegend, San Diego, CA, USA) (data not
shown).
4.4. Lectin Binding Assay
Resting or activated T cells were washed twice with cold phosphate buffered saline (PBS) and
incubated at 4 ◦C for 30 min with eFluor 660 fixable viability dye (eBioscience, Thermo Fisher
Scientific, Waltham, MA, USA), then fixed with 4% paraformaldehyde for 4 min at room temperature.
After washing the samples twice in PBS supplemented with 1% FBS and 0.1% sodium-azide
(fluorescence-activated cell sorting (FACS) buffer), the cells were incubated at 4 ◦C for 20 min with
fluorescein-labeled lectins or unlabeled Gal-1 (lectins used are listed in Table 1). The fluorescein-labeled
plant lectin kit (Vector Laboratories, Burlingame, CA, USA) was used according to the manufacturer’s
instructions. Recombinant galectin-1 was produced and characterized in our laboratory, as previously
described [15]. Gal-1-binding was detected as follows: after washing with FACS buffer, biotinylated
mouse monoclonal antibody to Gal-1 (2C1/6) was added and incubated at 4 ◦C for 45 min. Samples were
washed with cold FACS buffer before adding fluorescein isothiocyanate(FITC)-labeled streptavidin
and incubating the cells at 4 ◦C for 20 min. Finally, the samples were washed twice in FACS buffer.
Samples were analyzed with a FACSCalibur system (BD Biosciences, Franklin Lakes, NJ, USA) and
data were evaluated using FlowJo V10 software (BD Biosciences, Franklin Lakes, NJ, USA). The lectin
binding was evaluated on resting T cells within PBMCs or activated T cells by gating CD3+ cells with
PE/Cy5-conjugated anti-human CD3 antibody (BioLegend, San Diego, CA, USA).
4.5. Neuraminidase Treatment
Activated T cells (2 × 106/sample) were treated with α2-3,6,8 neuraminidase (α2-3,6,8 Neu, New
England BioLabs, Ipswich, MA, USA) according to the manufacturer’s instructions or left untreated.
Briefly, the cells were washed with PBS then incubated with 200 U of α2-3,6,8Neu in a total volume
of 40 µL glycobuffer (provided by the manufacturer) for 15 min at 37 ◦C. After washing the samples
with cold PBS, Gal-1 binding, viability staining, fixation, and flow cytometry analysis were done, as
described above.
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4.6. Quantitative Real-Time PCR (qPCR)
The qPCR assays were performed according to the MIQE (Minimum Information for Publication
of Quantitative Real-Time PCR Experiments) guidelines [55]. The names of genes are listed in
Table 2. Total RNA was extracted from activated T cells (1–3 × 106 cells) using PerfectPure RNA
Cultured Cell kit (5 PRIME, Gaithersburg, MD, USA) according to the manufacturer’s instructions with
on-column DNase digestion. The amount and quality of RNA were measured using NanoDrop-1000
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). For cDNA synthesis, 2 µg of total
RNA/reaction was reverse transcribed using RevertAid H Minus First Strand cDNA Synthesis Kit
(Thermo Fisher Scientific, Waltham, MA, USA) in the presence of 1.66 µM of oligo (dT) 18 and random
hexamer primers, 0.5 mMdNTP, 10 U RiboLock RNase Inhibitor, and 200 U RevertAid H Minus Reverse
Transcriptase for 60 min at 42 ◦C, then heated for 10 min at 70 ◦C. Quantitative PCR amplifications
were carried out with appropriate negative controls at least in duplicate. The reaction volume was
20 µL and composed of AccuPower 2 × Greenstar qPCR Master Mix (Bioneer, Alameda, CA, USA),
300–300 nM primers, and 40-fold diluted cDNA. For PCR amplifications, RotoGene3000 instrument
(Corbett Research, Sydney, Australia) was used. The qPCR program included: initial 95 ◦C for 15 min,
followed by repeated 45 cycles (95 ◦C for 15 s, 60–62 ◦C for 20 s, 72 ◦C for 20 s), and melting temperature
analysis increasing the temperature from 55 ◦C to 98 ◦C at 0. 5 ◦C/step with 8 sec stops between each
step. Quantitative real-time PCR data were analyzed using the Rotor Gene software (v6.1 build 93).
Relative mRNA levels, normalized to RPL27, were presented as log2 transformation of relative gene
expression, namely subtraction of Ct values (∆Ct = CtRPL27 − CtGOI). The mRNA expression ratios
were calculated using the following formula: ∆Ct × gene −∆Ct Y gene. Primer sequences were partly
taken from [56–59], or designed using the Universal Probe Library Assay Design program (Roche
Applied Science, Basel, Switzerland). Primer sequences used in the study are shown in Table 4.
Table 4. Primer sequences used in the study for the mRNA amplification of glycosylation enzymes.
Name Forward Primer Reverse Primer
RPL27 5′-CGCAAAGCTGTCATCGTG-3′ 5′-GTCACTTTGCGGGGGTAG-3′
MAN1A1 5′-TTGGGCATTGCTGAATATGA-3′ 5′-CAGAATACTGCTGCCTCCAGA-3′
MAN1A2 5′-GGAGGCCTACTTGCAGCATA-3′ 5′-GAGTTTCTCAGCCAATTGCAC-3′
MAN2A1 5′-CCTGGAAATGTCCAAAGCA-3′ 5′-GCGGAAATCATCTCCTAGTGG-3′
MAN2A2 5′-TCCACCTGCTCAACCTACG-3′ 5′-TGTAAGATGAGTGCGGTCTCC-3′
MGAT1 5′-CGGAGCAGGCCAAGTTC-3′ 5′-CCTTGCCCGCAGTCCTA-3′
MGAT4A 5′-CATAGCGGCAACCAAGAAC-3′ 5′-TGCTTATTTCCAAACCTTCACTC-3′
MGAT4B 5′-CACTCTGCACTCGCTCATCT-3′ 5′-CACTGCCGAAGTGTACTGTGA-3′
MGAT5 5′-GCTCATCTGCGAGCCTTCT-3′ 5′-TTGGCAGGTCACCTTGTACTT-3′
ST3GAL3 5′-TATGCTTCAGCCTTGATG-3′ 5′-TTGGTGACTGACAAGATGG-3′
ST3GAL4 5′-ATGTTGGCTCTGGTCCTG-3′ 5′-AGGAAGATGGGCTGATCC-3′
ST3GAL6 5′-TCTATTGGGTGGCACCTGTGGAAA-3 5′-TGATGAAACCTCAGCAGAGAGGCA-3′
ST6GAL1 5′-TGGGACCCATCTGTATACCACT-3′ 5′-ATTGGGGTGCAGCTTACGAT-3′
NEU1 5′-CCTGGATATTGGCACTGAA-3′ 5′-CATCGCTGAGGAGACAGAAG-3′
4.7. Statistical Analysis
Statistical analysis was performed using GraphPad Prism Version 7.01. In all statistical analyses,
an unpaired, two-tailed t-test was used to compare data obtained in T cells of healthy controls and
SLE patients. There was only one exception (Figure 4B), where paired two-tailed Student’s t-test was
chosen for the comparison of values from T cells of the same patient with or without neuraminidase
treatment. The significant differences were indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/18/
4455/s1.
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SLE Systemic lupus erythematosus
Gal-1 Galectin-1
NEU Neuraminidase
ConA Concanavalin-A
LCA Lens culinaris agglutinin
WGA Wheat germ agglutinin
PHA phytohaemagglutinin
PHA-L Phaseolus vulgaris leukoagglutinin
SNA Sambucus nigra agglutinin
MFI Median fluorescence intensity
MGAT1–5- Beta-N acetylglucosaminyltransferases
MAN Mannosidase
MGAT N-Acetyl glucosaminyltransferase
ST Sialyltransferase
SLEDAI-2K SLE disease activity index-2000
Anti-dsDNA Antibody to double-stranded DNA
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
FACS Fluorescence-activated cell sorting
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